Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
Roger Perlmutter leaves Merck after 7 years, joins board at InsitroRoger Perlmutter has brought a seven-year stint as head of R&D at Merck & Co/MSD to a close, Share XRoger Perlmutter leaves Merck after 7 years, joins board at Insitrohttps://pharmaphorum.com/news/roger-perlmutter-leaves-merck-after-7-years-joins-board-at-insitro/
New data reinforce Keytruda’s dominance in first-line lung cancerFive-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off Share XNew data reinforce Keytruda’s dominance in first-line lung cancerhttps://pharmaphorum.com/news/new-data-reinforce-keytrudas-dominance-in-first-line-lung-cancer/
Merck & Co signs multi-billion cancer drug development deal with Seattle GeneticsMerck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion Share XMerck & Co signs multi-billion cancer drug development deal with Seattle Geneticshttps://pharmaphorum.com/news/merck-co-signs/
Despite biosims, ulcerative colitis drugs still cost too much; ICERNone of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough Share XDespite biosims, ulcerative colitis drugs still cost too much; ICERhttps://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/
How companies can encourage more diversity and inclusion in pharmaSeptember is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares Share XHow companies can encourage more diversity and inclusion in pharmahttps://pharmaphorum.com/views-analysis-patients/how-companies-can-encourage-more-diversity-and-inclusion-in-pharma/
Merck & Co plans to file cough drug gefapixant after phase 3 successMerck & Co is planning to file a drug for unexplained or treatment-resistant cough after supportive results from Share XMerck & Co plans to file cough drug gefapixant after phase 3 successhttps://pharmaphorum.com/news/merck-co-plans-to-file-cough-drug-gefapixant-after-phase-3-success/
AZ halts COVID-19 vaccine after safety scare, as UK faces ‘second wave’It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than Share XAZ halts COVID-19 vaccine after safety scare, as UK faces ‘second wave’https://pharmaphorum.com/news/az-halts-covid-19-vaccine-after-safety-scare-as-uk-faces-second-wave/
Highlight Therapeutics trials second-line melanoma combo after immunotherapy failsCancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to Share XHighlight Therapeutics trials second-line melanoma combo after immunotherapy failshttps://pharmaphorum.com/news/highlight-therapeutics-trials-second-line-melanoma-combo-after-immunotherapy-fails/
